NCT04796493

Brief Summary

Mesenteric traction syndrome (MTS) is defined as hypotension, tachycardia and facial flushing in the first hour of surgery, caused by mesenteric traction/abdominal exploration. MTS occurs frequently during abdominal surgery, with incidence around 80 % during open surgery, and lower during minimally invasive surgery. MTS can be divided into different severities using the degree of facial flushing, with the most severe level of MTS being associated with increased postoperative morbidity. Today MTS is diagnosed and graded subjectively by the surgical team, with marked difficulty and limitations. Therefore the investigators developed a cut-off value using the Laser Speckle Contrast Imaging (LSCI), which the investigators wish to confirm in a new cohort, while also examining whether LSCI is interchangeable with digital thermography, which is simpler and cheaper to perfom. The investigators will measure facial perfusion during the first hour of surgery and take blood samples at predefined timepoints to use for biochemical verification of the different severities of MTS. Three cohorts we planned to include 45 open esophagectomies or gastrectomies 50 whipple surgery 20 robot assisted esophagectomies or gastrectomies These patients will be use in multiple articles examining different aspects of MTS One study examining LSCI and thermography for the identification and grading of MTS will use 60 patients undergoing open esophagectomy or gastrectomy or whipple surgery, in this study patients will not be excluded if they are found to be disseminated. However we ended up including 37 open esophagectomies - due to few patients undergoing open esophagectomy, this were included over a time period of almost 2,5 years 50 whipple 11 Robotic esophagectomies - due to LSCI being impossible to use on robotic esophagectomies and thermography being diffciult to fit on these patients and as such not being feasible

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for all trials

Timeline
15mo left

Started Mar 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Mar 2021Aug 2027

First Submitted

Initial submission to the registry

March 8, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 15, 2021

Completed
1 day until next milestone

Study Start

First participant enrolled

March 16, 2021

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
4.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 23, 2027

Expected
Last Updated

April 6, 2025

Status Verified

April 1, 2025

Enrollment Period

2.3 years

First QC Date

March 8, 2021

Last Update Submit

April 2, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Severity of MTS - measured facial perfusion

    Facial perfusion measured with LSCI and Digital Thermography

    first hour of surgery

Secondary Outcomes (10)

  • Biochemical markers of MTS - prostacyclin

    During surgery

  • Hemodynamics

    During surgery

  • Markers of postoperative impact of MTS - IL6 and endothelial damage markers

    During and after surgery

  • 30-day postoperative morbidity

    30 days post surgery

  • Incidence of objective MTS during whipples procedure with methylprednisolone prophylaxis

    During surgery

  • +5 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

3 cohorts * open esophagectomies * robotic assisted esophagectomies * whipples procedure

You may qualify if:

  • Undergoing curative surgery for esopageal, gastric, doudenal or pancreatic cancer

You may not qualify if:

  • Known flushing disease
  • Patients recieving NSAID and corticosteroid presurgery, Whipple is allowed to recieve single dose of 125 mg Methylprednisone as part of the standard of care at our facility.
  • Palliative surgery
  • Surgery not completed due to disseminated disease - patients will still be used in examination of LSCI and Thermography analysis even if desiminated

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rigshospitalet

København Ø, Capital Region, 2100, Denmark

Location

Study Officials

  • August Olsen

    Rigshospitalet, Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD PhD student

Study Record Dates

First Submitted

March 8, 2021

First Posted

March 15, 2021

Study Start

March 16, 2021

Primary Completion

June 30, 2023

Study Completion (Estimated)

August 23, 2027

Last Updated

April 6, 2025

Record last verified: 2025-04

Locations